Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A needed information source.

M C Frederiksen1

  • 1Department of Clinical Obstetrics and Gynecology, Feinberg Medical School, Northwestern University, Chicago, Illinois, USA. mcf810@northwestern.edu

Clinical Pharmacology and Therapeutics
|January 1, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physiologic changes in pregnancy and their effect on drug disposition.

Seminars in perinatology·2001
Same author

A randomized trial of misoprostol versus extra-amniotic sodium chloride infusion with oxytocin for induction of labor.

American journal of obstetrics and gynecology·2000
Same author

Placenta previa: a 22-year analysis.

American journal of obstetrics and gynecology·1999
Same author

Fetal heart rate characteristics at 25 to 28 weeks' gestation.

American journal of perinatology·1998
Same author

A comparison of once-daily and 8-hour gentamicin dosing in the treatment of postpartum endometritis.

Obstetrics and gynecology·1996
Same author

Single-dose methotrexate for the treatment of ectopic pregnancy: Northwestern Memorial Hospital three-year experience.

American journal of obstetrics and gynecology·1996
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
See all related articles

Most drug information for pregnancy focuses on birth defects and newborn health. A critical need exists for resources addressing safe and effective drug therapy for maternal conditions during pregnancy.

Area of Science:

  • Pharmacology
  • Maternal-Fetal Medicine
  • Drug Safety

Background:

  • Current drug information for pregnancy primarily details teratogenicity and neonatal effects.
  • Therapeutic considerations for managing maternal diseases during pregnancy are often lacking.
  • Physiological changes during pregnancy are frequently overlooked in standard drug dosing.

Observation:

  • Existing drug safety resources for pregnancy predominantly focus on congenital anomalies and neonatal adaptation.
  • Information addressing the therapeutic management of maternal conditions in pregnant individuals is not readily accessible.
  • Standard adult drug dosages are often presumed appropriate for pregnant patients despite significant physiological alterations.

Findings:

  • A significant gap exists in readily available information regarding the therapeutic use of medications in pregnant populations.

Related Experiment Videos

  • Current resources fail to adequately address the complexities of drug therapy for maternal diseases during pregnancy.
  • The assumption of unchanged drug dosages from healthy adults to pregnant individuals is prevalent but unsupported.

    • Implications:

    • Development of specialized informational resources is crucial for optimizing drug therapy in pregnant women.
    • Addressing therapeutic issues in pregnancy will improve maternal and fetal health outcomes.
    • Evidence-based guidelines for drug dosing and selection in pregnancy are urgently needed.